Orlistat is an effective and well-tolerated antiobesity drug, which can be employed as an
CLINICAL PHARMACOLOGY
Lactones* / pharmacology Lactones* / therapeutic use Male Obesity / complications Obesity Pharmacology
Furman, in xPharm: The Comprehensive Pharmacology Reference, 2007 Introduction
Orlistat works by inhibiting gastric and pancreatic lipases, the enzymes that break down triglycerides in the intestine
Dr
Because orlistat may decrease the absorption of fat-soluble vitamins, a standard multiple-vitamin supplement
Metreleptin and Setmelanotide are currently indicated for rare obesity syndromes, and 5
Orlistat
Methods: Enzyme assays were performed with porcine pancreatic lipase and para-Nitrophenyl Palmitate (pNPP) in pH 8
Objective: To determine the weight-reducing efficacy of orlistat, a novel gastrointestinal lipase inhibitor, and to define the optimal dosage regimen and establish the tolerability of the drug when used for a 6-month treatment period
1
Mulligan BS, It is concluded that systemic exposure of orlistat is negligible; at a clinically efficacious dose level, orlistat is unlikely to produce systemic lipase inhibition
This analysis was performed to elucidate the relationship between orlistat dose and intensity of inhibition of dietary fat absorption (assessed by measuring fecal fat excretion)
XENICAL (orlistat) is a gastrointestinal lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats
Long-term therapy is indicated for obese patients with a BMI of 30 kg/m 2 or greater and for patients with a BMI of 27 kg/m 2 who also have diabetes, dyslipidemia, or hypertension
2019 Mar;92:170-192
10